CClinicalTrials.gg
CompletedNCT02364375Updated Feb 4, 2021

Usability Evaluation of Menai CPAP Masks

An interventional study of Menai mask (full face) and Menai Standard mask (full face) in Obstructive Sleep Apnea, sponsored by ResMed. Completed at 1 site in Australia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by ResMed · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the subjective performance of the Menai mask systems (full face, nasal, and pillows variants), compared against Comparison mask systems.

Read the detailed description

The study will evaluate the subjective seal, comfort, stability, usability, and humidification performance of the prototype mask systems in CPAP established patients. The performance of the prototype Menai mask systems (full face, nasal, and pillows variants) will be subjectively assessed through user questionnaires based on an 11-point Likert scale, and will be compared against Comparison masks.

The prototype masks share the same parts (cushion, frame, headgear), with the difference being that the Menai masks feature a novel vent and humidification system.

02

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • sleep
  • apnea
  • OSA
  • CPAP
03

In context

Sleep Apnea, Obstructive

2,198 studies on the registry are indexed under Sleep Apnea, Obstructive; 469 are open to participants now.

This study's enrollment of 30 is below the median of 53 across 1,448 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

ResMed is the lead sponsor of 105 studies on the registry; 13 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participants willing to provide written informed consent
  • Participants who can read and comprehend written and spoken English
  • Participants who are over 18 years of age
  • Participants who have been diagnosed with OSA
  • Participants who have been established on CPAP for ≥ 6 months
  • Participants who are currently using the same mask type/variant as the interventional mask system to be evaluated

Exclusion criteria

Exclusion Criteria:

  • Participants who are not able to provide written informed consent
  • Participants who are unable to comprehend written and spoken English
  • Participants who are pregnant
  • Participants who are unsuitable to participate in the study in the opinion of the researcher
  • Participants with a pre-existing lung disease or a condition that would predispose them to pneumothorax (e.g. COPD, lung cancer; fibrosis of the lungs; recent (\< 2years) case of pneumonia or lung infection, lung injury)
  • Participants who cannot participate for the duration of the trial
  • Participants who are established on bi-level support therapy
  • Participants who are not currently using the same mask type/variant as the interventional mask system to be evaluated
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Full Face

    Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (full face) and Comparison Menai Standard mask (full face) for 7 nights each.

    Device: Menai mask (full face) · Device: Menai Standard mask (full face)

  • Experimental
    Nasal

    Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (nasal) and Comparison Menai Standard mask (nasal) for 7 nights each.

    Device: Menai mask (nasal) · Device: Menai Standard mask (nasal)

  • Experimental
    Pillows

    Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (pillows) and Comparison Menai Standard mask (pillows) for 7 nights each.

    Device: Menai mask (pillows) · Device: Menai Standard mask (pillows)

Interventions

  • DeviceMenai mask (full face)

    Prototype mask system (full face variant) with novel vent and humidification system

  • DeviceMenai Standard mask (full face)

    Prototype mask system (full face variant) with conventional vent and humidification system

  • DeviceMenai mask (nasal)

    Prototype mask system (nasal variant) with novel vent and humidification system

  • DeviceMenai Standard mask (nasal)

    Prototype mask system (nasal variant) with conventional vent and humidification system

  • DeviceMenai mask (pillows)

    Prototype mask system (pillows variant) with conventional vent and humidification system

  • DeviceMenai Standard mask (pillows)

    Prototype mask system (pillows variant) with conventional vent and humidification system

06

What researchers measure

Primary outcomes

  1. Usability Performance Evaluation

    Evaluation of the usability performance (seal, comfort, etc) of the Menai masks, compared to the Comparison Menai Standard masks.

    Time frame: 2 weeks

Secondary outcomes

  1. Humidification Performance Evaluation

    Evaluation of the humidification performance of the Menai masks (passive humidification), compared to the Comparison Menai Standard masks (active humidification).

    Time frame: 2 weeks

07

Study locations

1 site
  • ResMed Sleep Research Centre
    Sydney, New South Wales 2153, Australia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02364375
Lead sponsor
ResMed
Responsible party
Sponsor
First posted
Feb 18, 2015
Start date
May 2015
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Feb 4, 2021

Study contacts

Klaus Schindhelm, BE PhD
principal investigator · Graduate School of Biomedical Engineering, University of New South Wales, Sydney Australia and Applied Research, ResMed Ltd Sydney Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion